Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR)
Launched by SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES · Aug 30, 2006
Trial Information
Current as of August 11, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Cases with rhegmatogenous retinal detachment complicated by PVR grade C
- Exclusion Criteria:
- • History of pars plana vitrectomy for PVR grade C
- • History of silicone oil injection
- • History of ocular trauma
- • Diabetic retinopathy
- • Glaucoma
- • Giant retinal tear
About Shahid Beheshti University Of Medical Sciences
Shahid Beheshti University of Medical Sciences, located in Tehran, Iran, is a leading institution dedicated to advancing healthcare through innovative research and education. Renowned for its commitment to medical excellence, the university actively sponsors clinical trials aimed at improving patient outcomes and enhancing medical practices. With a multidisciplinary approach, it collaborates with healthcare professionals and researchers to explore new treatments and interventions, contributing significantly to the global body of medical knowledge. The institution is dedicated to upholding the highest ethical standards in research, ensuring the safety and well-being of participants while fostering a culture of scientific inquiry and discovery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Trial Officials
Hamid Ahmadieh, MD
Principal Investigator
Ophthalmic Research Center of Shaheed Beheshti Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials